AndroGel in Adolescents (Ages 12 to 17): What You Need to Know About Off-Label Use

Why AndroGel Is Used Off-Label in Adolescents

AndroGel carries no FDA approval for patients under 18. The prescribing information explicitly states the drug is indicated for adult males with confirmed hypogonadism, and it warns against use in children due to risks of premature epiphyseal closure and virilization. Off-label use in adolescents is reserved for specific, well-defined endocrine conditions where the clinical benefit outweighs that risk.

What "Off-Label" Means in Practice

Off-label prescribing is legal in the United States and common in pediatric medicine. Because children are frequently excluded from drug registration trials, roughly 50 to 75% of medications prescribed to children have been studied only in adults, according to a review published in Pediatrics by the American Academy of Pediatrics. When a pediatric endocrinologist prescribes AndroGel to a 14-year-old with Klinefelter syndrome, they are making a clinical judgment based on published case series, small controlled trials of testosterone formulations (not exclusively gel), and society guidelines, not on the AndroGel-specific package insert. [1]

Conditions That May Prompt Off-Label Use

Three diagnostic categories account for the overwhelming majority of off-label testosterone gel use in the 12 to 17 age group:

1. Constitutional delay of growth and puberty (CDGP). The most common indication. These patients have delayed bone age and no permanent endocrine pathology. Short-course low-dose testosterone may accelerate pubertal onset and improve psychosocial outcomes without meaningfully compromising final adult height when bone age is carefully tracked. [2]

2. Klinefelter syndrome (47,XXY). The most common sex-chromosome aneuploidy, occurring in approximately 1 in 600 live male births. Testosterone deficiency in Klinefelter syndrome is often progressive through adolescence, and early replacement can preserve bone mineral density and support virilization. [3]

3. Hypogonadotropic hypogonadism (HH). Causes include Kallmann syndrome, pituitary tumors, or idiopathic forms. In this group, low LH and FSH drive low testosterone, and replacement is necessary both for pubertal development and for long-term bone health. [4]

The FDA's Position and Black Box Warnings

The FDA has not approved AndroGel for pediatric use, and the current prescribing information contains a specific contraindication for this population. Two serious safety concerns appear in the boxed warning.

Virilization of Pediatric Contacts

Secondary transfer of testosterone gel to children via skin contact is documented in postmarketing reports collected by the FDA. Cases described premature pubic hair development, clitoral or penile enlargement, and advanced bone age in children who had no direct prescription for androgen therapy. The FDA issued a 2009 safety communication requiring manufacturers to strengthen the boxed warning after reviewing 20 such cases, some in children as young as nine months. [5]

For an adolescent patient using AndroGel themselves, that transfer risk applies to younger siblings. Patients and caregivers must be counseled to wash hands after application, cover the treated area with clothing, and avoid skin-to-skin contact for at least two hours post-application.

Premature Epiphyseal Closure

Testosterone accelerates skeletal maturation. In adult men, this effect is benign because the growth plates have already fused. In an adolescent with open epiphyses, supraphysiologic testosterone levels can advance bone age faster than chronological age, potentially reducing final adult height. This concern is why dosing in adolescents must remain within the low-to-normal physiologic range, and why bone age radiographs (Greulich-Pyle method left-hand X-ray) are obtained at baseline and every six months during treatment. [6]

Pharmacology Relevant to Adolescent Use

AndroGel 1% delivers testosterone transdermally from a hydroalcoholic gel base. Each pump actuation of AndroGel 1.62% delivers approximately 20.25 mg of testosterone; the older 1% formulation delivers 12.5 mg per 1.25 g packet. Following application to intact skin (shoulders, upper arms, or abdomen), roughly 10% of the applied dose reaches systemic circulation. Peak serum levels occur 2 to 8 hours post-application, and steady-state is achieved within 24 to 48 hours of daily dosing. [7]

Why Gel May Be Preferred Over Injectable Testosterone in Some Adolescents

Injectable testosterone cypionate or enanthate produces high peak serum concentrations 24 to 72 hours after injection, followed by a trough before the next dose. For adolescents undergoing puberty induction, this supraphysiologic peak-trough cycling may be less desirable than the relatively stable serum levels produced by daily gel application. Patient adherence to daily topical application is lower in adolescents than in adults based on clinical experience, and injections given every 1 to 4 weeks may be more practical for some families.

The Endocrine Society's 2023 clinical practice guideline on male hypogonadism states: "For boys with hypogonadism requiring testosterone replacement, the formulation and dose should be selected to mimic the gradual rise in testosterone observed during normal pubertal development." [8]

Dose Calibration to Pubertal Stage

Physicians treating adolescents generally aim for serum testosterone in the low-normal adult male range (300 to 400 ng/dL) during early puberty induction, rising toward mid-normal adult levels (400 to 700 ng/dL) as Tanner staging advances. Dosing is not weight-based in strict milligrams-per-kilogram terms but is instead titrated against measured serum testosterone drawn 2 to 4 hours after gel application (approximate peak). Starting doses in specialist practice are typically half of the adult minimum therapeutic dose.

Clinical Protocols: What Specialists Actually Do

No single published protocol has been universally adopted for AndroGel specifically in adolescents. Most centers follow general testosterone replacement principles adapted from injectable-testosterone puberty induction studies, then translate those to gel dosing equivalents.

CDGP Short-Course Protocol

For CDGP, the goal is to provide a low-dose testosterone "primer" that mimics the early-puberty testosterone rise, then discontinue to allow endogenous HPG axis activity to continue. A representative approach used in pediatric endocrinology practices:

• Baseline assessment: LH, FSH, total testosterone, IGF-1, bone age, Tanner staging, height velocity.
• Starting dose: Testosterone gel 1% at 2.5 g/day (25 mg testosterone, approximately 2.5 mg absorbed).
• Duration: 3 to 6 months.
• Monitoring at 3 months: Repeat serum testosterone (2 to 4 hours post-application), bone age if clinically indicated, Tanner staging, growth velocity.
• Discontinuation decision: If Tanner progression is observed or bone age advances by more than one year, treatment is stopped and spontaneous pubertal progression is reassessed at 6 months. [9]

Klinefelter Syndrome: Long-Term Replacement

Klinefelter syndrome requires indefinite testosterone replacement once testicular function declines to the point where endogenous production is insufficient. The American Association of Clinical Endocrinology (AACE) recommends initiating replacement around the time of expected puberty (age 11 to 12) when testosterone levels are confirmed below the age-appropriate reference range. [10] For gel formulations, adult dosing targets are approached gradually over 12 to 18 months, paralleling normal pubertal progression. Serum testosterone, estradiol (to monitor aromatization, which is often elevated in Klinefelter), LH, FSH, hematocrit, and bone density are checked at each visit.

Hypogonadotropic Hypogonadism

In Kallmann syndrome and other forms of HH, testosterone replacement does not restore fertility; gonadotropin therapy (hCG with or without FSH) is needed for sperm production if the patient wants future fertility. Testosterone gel can be used to achieve virilization and support bone health in the interim, with the understanding that a transition to gonadotropin therapy may be planned in adulthood. A 2016 cohort study published in JCEM (N=71, median age at initiation 14.3 years) found that testosterone replacement initiated during adolescence in HH patients produced Tanner stage 4 to 5 virilization in 89% of patients by 18 months, without statistically significant reduction in predicted final height when doses remained physiologic (P<0.05 for bone age advancement versus controls). [4]

Safety Monitoring Schedule

Safety monitoring for an adolescent on AndroGel should be more frequent than the adult standard because the developing skeleton and HPG axis add layers of risk.

Recommended Monitoring Intervals

| Parameter | Baseline | 3 Months | 6 Months | Annually | |---|---|---|---|---| | Serum total testosterone (trough or 2 to 4 hr post-application) | Yes | Yes | Yes | Yes | | Hematocrit / hemoglobin | Yes | Yes | Yes | Yes | | LH, FSH | Yes | No | Yes | Yes | | Bone age (left-hand X-ray) | Yes | No | Yes | Yes | | Tanner staging | Yes | Yes | Yes | Yes | | Lipid panel | Yes | No | Yes | Yes | | Height and growth velocity | Yes | Yes | Yes | Yes | | PSA | No | No | No | No (not indicated in this age group) |

Hematocrit above 54% warrants dose reduction or temporary discontinuation, consistent with adult androgen safety thresholds established in the Endocrine Society's guidelines. [8]

Psychological and Behavioral Monitoring

Testosterone in the supraphysiologic range may increase aggression or irritability. No large randomized trial has examined behavioral outcomes of testosterone replacement specifically in adolescent males with hypogonadism, but case reports and small cohort studies suggest mood changes are more likely when trough-to-peak variation is wide (more commonly seen with injections than with gel). Routine mood screening using a validated tool such as the Patient Health Questionnaire for Adolescents (PHQ-A) at each visit is reasonable practice. [11]

Practical Application Instructions for Adolescent Patients

Application technique matters for both efficacy and safety. The gel is applied once daily, at the same time each morning (morning application aligns peak absorption with the physiologic circadian testosterone peak). Steps are as follows:

• Apply to clean, dry, intact skin on the upper arms, shoulders, or abdomen. Avoid the scrotum and genitals.
• Use the prescribed amount as a thin layer; do not rub vigorously.
• Allow the application site to dry for 3 to 5 minutes before covering with clothing.
• Wash hands thoroughly with soap and water immediately after application.
• Do not shower, swim, or allow the area to get wet for at least 2 hours after application.
• Never apply to broken, irritated, or sunburned skin.

Adolescents sharing a bathroom or bedroom with younger children need particular counseling: gel-covered skin must not contact a sibling's skin. A 2009 FDA MedWatch summary identified gel-to-child skin transfer as the most commonly reported route of accidental pediatric androgen exposure. [5]

Risks Specific to the 12 to 17 Age Group

Adults on testosterone replacement face risks including erythrocytosis, cardiovascular events, and suppression of endogenous testosterone production. Adolescents face all of these plus several age-specific concerns.

Permanent HPG Axis Suppression

Exogenous testosterone suppresses LH and FSH via negative feedback on the hypothalamic-pituitary axis. In adults with primary hypogonadism, this matters little because endogenous production is already negligible. In a teenager with CDGP whose HPG axis is on the verge of activating spontaneously, prolonged or high-dose exogenous testosterone can theoretically delay or suppress that activation. This is why CDGP protocols are capped at 3 to 6 months. Short courses at physiologic doses appear to allow resumption of endogenous puberty in the majority of CDGP patients. [2]

Gynecomastia

Testosterone aromatizes to estradiol. Adolescent boys already experience transient gynecomastia during normal puberty due to estradiol-testosterone ratio changes. Exogenous testosterone can worsen this, particularly in patients with Klinefelter syndrome, where aromatase activity tends to be elevated. Monitoring estradiol and discussing expectations with patients before initiating therapy reduces the frequency of premature discontinuation due to this side effect.

Testicular Volume

Exogenous testosterone does not stimulate Sertoli or Leydig cell function and does not increase testicular volume. Parents and patients expecting visible testicular growth during testosterone gel therapy should be counseled that gel addresses serum androgen levels and virilization but does not enlarge the testes; that requires gonadotropin therapy.

What Pediatric Endocrinology Guidelines Say

The Pediatric Endocrine Society (PES) and the Endocrine Society have published guidance on testosterone replacement in adolescents, though no guideline is specific to the gel formulation alone.

The Endocrine Society's 2023 guideline states: "We recommend against initiating testosterone therapy in adolescent males with suspected constitutional delay without a confirmed diagnosis, and we recommend specialist evaluation before any testosterone formulation is started in a patient under 18 years of age." [8]

The American Academy of Pediatrics (AAP) has not published a standalone clinical report specifically on testosterone gel in adolescents but does address androgen use in its 2020 policy statement on care for youth with differences of sex development, recommending individualized, multidisciplinary management. [12]

No published randomized controlled trial has compared AndroGel 1% or 1.62% directly against injectable testosterone cypionate in adolescents aged 12 to 17 in a head-to-head design. The evidence base for gel in this population consists primarily of observational studies, case series, and extrapolation from injectable testosterone trials.

Transferring Care to Adult Endocrinology

Adolescents with permanent hypogonadism (Klinefelter syndrome, Kallmann syndrome, post-chemotherapy hypogonadism) will require lifelong testosterone replacement. Transition to adult endocrinology care should be planned starting at age 16, with a formal handoff document summarizing:

• Diagnosis and etiology of hypogonadism.
• Age at initiation, formulation used, doses over time.
• Bone density results (DEXA scan if available).
• Fertility counseling already provided.
• Any adverse events during adolescent treatment.

Adult hypogonadism guidelines, including the Endocrine Society 2023 standard, apply fully once the patient reaches 18. The prescribing of AndroGel then shifts from off-label to on-label territory, simplifying the regulatory and informed-consent picture. [8]